Golden State Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Golden State Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-63	Closed	-$3.56K	–	1630
2026 Q1	$3.56K	Hold	63	–	–	﹤0.01%	1273
2025 Q4	$3.74K	Sell	63 -127	-67%	-$6.91K	﹤0.01%	1287
2025 Q3	$10.3K	Buy	190 +63	+50%	+$3.6K	﹤0.01%	1097
2025 Q2	$6.98K	Hold	127	–	–	﹤0.01%	1159
2025 Q1	$8.98K	Hold	127	–	–	﹤0.01%	1019
2024 Q4	$8.35K	Buy	+127	New	+$8.51K	﹤0.01%	1005

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Golden State Wealth Management's BMRN Position: Q2 2026 in Review

Golden State Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 63 shares — an estimated $3.56K sold.

Golden State Wealth Management first reported a position in BMRN in Q4 2024 and held it in 6 quarters. The position peaked at $10.3K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Golden State Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Golden State Wealth Management sold 63 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.56K.
Golden State Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Golden State Wealth Management's BioMarin Pharmaceuticals position peaked at $10.3K in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.